The overall goal of the proposed Seattle Primary Infection Program (SeaPIP) will be to define features of acute HIV-1 infection important to conferring a long-term advantage in controlling HIV-1 infection. State-of-the-art immunologic and virologic technologies will be brought to bear to discern biological mechanisms underlying host control. Our immunology project will be focused on identifying virus-specific immune responses as they develop in the newly infected host, and the effector cells of the immune response that correlate with virologic control. Two virology projects are proposed. One will identify the earliest targets of host-imposed viral genome selection, the reservoirs of infection under HAART, and the influence of therapies and host responses on this residual core of HIV-1 infection. The second virology project will define the impact of mutational changes that occur in the viral infection process on viral fitness in different host cell environments. We will further integrate these studies by defining host immune responses and virologic properties as functions of the following: time of infection, the time post-infection that therapy is initiated, and the T cell changes and viral rebound detected upon interruption or discontinuation of therapy. Senior investigators with long-term collaborative records in the field of primary HIV infection have been assembled to integrate cutting edge immunological, virologic and bioinformatics technologies with clinical observations. In support of these efforts, the program will include an experienced Clinical Core that will mount an aggressive recruitment effort focusing on new enrollment of patients in the earliest stages of HIV infection, as well as continue to monitor a high priority subset of 25 of the 143 patients in active follow-up in our Primary Infection Clinic (PIC) Cohort. A Virology Core will be responsible for receiving and storing specimens, specimen processing, virus isolation in tissue culture, viral load measurements, and drug resistance mutation testing. Lastly, an Administrative Core will function to coordinate continuous interactions between the program components, including facilitating scientific coordination, data and specimen management, fiscal oversight, and support for regulatory compliance, as well as providing statistical support for all Projects and Cores.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI057005-01
Application #
6696848
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Program Officer
Young, Janet M
Project Start
2003-09-30
Project End
2008-03-31
Budget Start
2003-09-30
Budget End
2004-03-31
Support Year
1
Fiscal Year
2003
Total Cost
$834,370
Indirect Cost
Name
University of Washington
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Stekler, Joanne D; Milne, Ross; Payant, Rachel et al. (2018) Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med 15:e1002537
Moore, Camille M; MaWhinney, Samantha; Forster, Jeri E et al. (2017) Accounting for dropout reason in longitudinal studies with nonignorable dropout. Stat Methods Med Res 26:1854-1866
Obermeit, Lisa C; Beltran, Jessica; Casaletto, Kaitlin B et al. (2017) Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining ""symptomatic"" versus ""asymptomatic"" HAND. J Neurovirol 23:67-78
Hu, Xintao; Valentin, Antonio; Rosati, Margherita et al. (2017) HIV Env conserved element DNA vaccine alters immunodominance in macaques. Hum Vaccin Immunother 13:2859-2871
Patel, Rena C; Baeten, Jared M; Heffron, Renee et al. (2017) Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data. J Acquir Immune Defic Syndr 75:91-96
Collier, Ann C; Chun, Tae-Wook; Maenza, Janine et al. (2016) A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned. Biores Open Access 5:15-21
Magaret, Amalia S; Mujugira, Andrew; Hughes, James P et al. (2016) Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clin Infect Dis 62:456-61
Johnston, Christine; Harrington, Robert; Jain, Rupali et al. (2016) Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant 22:149-56
Fife, Kenneth H; Mugwanya, Kenneth; Thomas, Katherine K et al. (2016) Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)-Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2-Coinfected Individuals. J Infect Dis 213:1573-8
Ma, Qing; Vaida, Florin; Wong, Jenna et al. (2016) Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol 22:170-8

Showing the most recent 10 out of 141 publications